Skip to main content

Home/ Cancer/ Group items tagged topical

Rss Feed Group items tagged

Matti Narkia

Safety evaluation of topical applications of ethanol on the skin and inside the oral ca... - 0 views

  •  
    Safety evaluation of topical applications of ethanol on the skin and inside the oral cavity. Lachenmeier DW. J Occup Med Toxicol. 2008 Nov 13;3:26. PMID: 19014531 doi:10.1186/1745-6673-3-26
Matti Narkia

New data on link between cancer and nutrition discussed at European symposium - 0 views

  •  
    European experts in cancer and nutrition are meeting in Zurich, Switzerland late this month to discuss cutting-edge research in one of the most important and fiercely debated topics in cancer prevention: the link between diet and cancer. There is growing evidence that many cancers may be prevented through healthy lifestyle, including a nutritionally balanced diet. In addition, nutritional problems can also have a negative impact on cancer management and the lives of patients. Other presentations will include new data on topics such as: Childhood nutrition and later breast cancer risk The anti-tumour effects of green tea Malnutrition and patient distress in cancer Possible anti-tumour effects of soy extracts in mice Estrogens in beef and cancer risk
Matti Narkia

Mechanisms of Berberine (Natural Yellow 18)-Induced Mitochondrial Dysfunction: Interact... - 0 views

  •  
    Mechanisms of berberine (natural yellow 18)-induced mitochondrial dysfunction: interaction with the adenine nucleotide translocator. Pereira CV, Machado NG, Oliveira PJ. Toxicol Sci. 2008 Oct;105(2):408-17. Epub 2008 Jul 3. PMID: 18599498 doi: 10.1124/jpet.107.128017 The data from the present work appear to show that berberine also presents some degree of toxicity to "nontumor" systems, which should be carefully understood. ANT inhibition in nontumor cells by berberine would be responsible for a decrease in energy production and could also result in MPT induction. To the best of our knowledge, no full toxicity assessment exists for berberine in humans, although its use in several commercially available supplements suggests that the compound may present a relatively wide safety interval. In fact, a study with patients with congestive heart failure treated with 1.2 g/day of oral berberine revealed low toxicity and resulted into an average plasma concentration of 0.11 mg/l which would translate into 0.3µM (Zeng and Zeng, 1999Go). Repeated cumulative treatments, alternative forms of formulation (e.g., topical application vs. injection) or more importantly, active mitochondrial accumulation due to its positive charge would be expected to increase its concentration in cells into the range of concentrations used in this study. Empirical data from nontraditional medicines plus the use of extensive clinical assays would allow the use of berberine as a promising antimelanoma agent while maintaining its safety for humans. In radial/vertical forms of melanoma, a possible topical application of berberine would also be possible, thus minimizing side effects on other organs. In conclusion, the present work identifies the ANT as an important target for berberine, with clear relevance for its proposed antitumor effects.
Matti Narkia

Comprehensive Cancer Information - National Cancer Institute - cancer.gov - 0 views

  •  
    The National Cancer Institute's research programs are extensive and contain many innovative initiatives. I invite you to explore our Web site to find out more about the exciting work being conducted here at NCI and by NCI-supported scientists throughout the country. You will also find valuable cancer-related information of all kinds. For the general public, patients, and health professionals, we offer consumer-oriented information on a wide range of topics as well as comprehensive descriptions of our research programs and clinical trials. Scientists will find detailed information on specific areas of research interest and funding opportunities.
Matti Narkia

DCA Update - Big Pharma/Glacial Rate of Progress | Uncommon Descent - 0 views

  •  
    Dichloroacetate (DCA) Promising for Endometrial Cancer DCA virtually disappeared from the news about a year ago when it was forced off the open market by the FDA and all research into its efficacy as a cancer therapeutic had to go through officially sanctioned channels. I've kept track of it all this time through Google Email Alerts. This is the first bit of news on it in relation to cancer in a long time.
1 - 5 of 5
Showing 20 items per page